#United States #oncology #South San Francisco #IDEAYA #ATTMOS

IDEAYA Biosciences and ATTMOS Collaboration: Revolutionizing Oncology Drug Discovery

In a groundbreaking move, IDEAYA Biosciences, Inc. has announced a strategic collaboration with ATTMOS aimed at accelerating the discovery of first-in-class oncology therapeutics. With the integration of advanced AI and machine learning technologies, this partnership is set to pave the way for innovative approaches to combat previously considered undruggable cancer targets, marking a significant advancement in precision medicine.

Harnessing Computational Power for Drug Development

IDEAYA Biosciences, recognized as a leader in precision oncology, is currently focused on the identification and development of targeted therapies for cancer patients. By collaborating with ATTMOS, a company that emphasizes the integration of academic research with industrial applications, IDEAYA seeks to enhance its capabilities in drug discovery. This partnership is particularly exciting as it promises to exploit a physics-based computational small molecule discovery platform, designed to rapidly unlock novel oncology targets that have been beyond reach.

The collaboration brings together IDEAYA's strong foundation in structural biology and drug discovery with ATTMOS's expertise in computational chemistry methods, high-performance computing, and software development. By combining these strengths, the teams aim to create a systematic workflow for high-throughput absolute binding free energy perturbation predictions (ABFEP) of drug candidate molecules. This innovative approach is expected to facilitate the identification of viable drug candidates in a shorter timeframe, improving the odds of success for novel biologically-targeted treatments.

Overcoming Current Limitations in Drug Discovery

Michael White, Ph.D., the Chief Scientific Officer of IDEAYA, emphasized that traditional drug discovery efforts using AI and machine learning have largely focused on existing drugged targets or well-characterized biological classes. Unfortunately, these techniques often fall short when applied to first-in-class oncology targets. However, IDEAYA's commitment to enhancing its computational drug discovery framework positions it to tackle these difficult challenges, ultimately aiming for breakthroughs in treating cancers previously deemed hard to target.

IDEAYA’s Chief Technology Officer, Paul Barsanti, Ph.D., further highlighted that their collaboration with ATTMOS aims to engineer novel solutions for drug discovery at scale, which could significantly improve the efficiency and speed of oncology treatments by targeting difficult biological substrates.

The initiative will utilize the Amber molecular dynamics suite, acclaimed for its GPU-accelerated free energy simulation capabilities. This technological backbone is set to underpin the collaboration's active learning cycles, which will be informed by comprehensive ground-truth datasheets from IDEAYA's successful wet-lab campaigns. This methodology will enable an extensive screening of vast chemical space libraries, assisting in the precise identification of small molecule ligands for new oncology targets, thus enriching the therapeutic landscape for patients.

The Future of Oncology Therapies

In conclusion, the collaboration between IDEAYA Biosciences and ATTMOS signifies a pivotal advancement in oncology drug discovery. By leveraging AI and cutting-edge computational methodologies, the partnership strives to surmount existing limitations on drug discovery processes. As they work together to uncover new treatments for hard-to-target cancers, the implications of their successes could resonate throughout the pharmaceutical landscape, providing hope for patients and healthcare professionals alike.

About IDEAYA Biosciences

IDEAYA Biosciences is devoted to the advancement of precision medicine in oncology, focusing on targeted therapies guided by molecular diagnostics. The company is at the forefront of identifying and validating biomarkers that ensure patients benefit from specific treatments, pushing the boundaries of what is possible through research and innovative drug discovery.

About ATTMOS

Established in early 2022, ATTMOS is an innovative company formed by a diverse team of academic professionals from prestigious institutions. Its mission is to innovate in drug discovery by bridging industry and academia, striving to make pioneering technologies accessible and affordable overall.

As the collaboration unfolds, IDEAYA and ATTMOS anticipate remarkable breakthroughs in the identification and development of promising oncology therapeutics that could transform patient outcomes in the years to come.